Abbott Laboratories ( (ABT) ) has released its Q3 earnings. Here is a breakdown of the information Abbott Laboratories presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories is a global healthcare company that specializes in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries worldwide.
In its third-quarter 2025 earnings report, Abbott Laboratories reported a 6.9% increase in sales, with organic sales growth of 5.5% or 7.5% when excluding COVID-19 testing-related sales. The company also reaffirmed its full-year guidance, highlighting its strong financial performance and strategic advancements.
Key financial highlights include a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30. The company’s operating margin improved to 18.1% on a reported basis and 23.0% on an adjusted basis. Abbott also announced regulatory approvals for its innovative medical devices, such as the TriClip and Navitor systems, which are expected to drive future growth.
Abbott’s diverse product portfolio and strategic initiatives have positioned it for continued success, with significant growth observed in its Medical Devices and Nutrition segments. The company reported double-digit growth in Diabetes Care and strong performance in its Adult Nutrition products.
Looking ahead, Abbott remains optimistic about its long-term growth prospects, supported by its robust product pipeline and strategic focus on innovation. The company continues to aim for durable value creation for its shareholders, maintaining its position as a leader in the healthcare industry.